Genepeutic Bio Co., Ltd.
1010, Shinawatra Tower 3, 12 th Fl., Vibhavadi-Rangsit Rd.,
Chatuchak, Chatuchak, Bangkok, Thailand 10900
Tel: +66 65 989 4600
5th April 2021
Genepeutic Bio and NSTDA sign an Investment Deal Agreement.
This partnership strengthens the local scientific innovation start-up company and supports Thailand into a medical hub for the therapeutic applications in cell and gene immunotherapies for cancers and other potential diseases.
CHATUCHAK, Bangkok (April 5, 2021) – Genepeutic Bio Co., Ltd., a start-up contract development and manufacturing organization (CDMO) company for clinical-stage cell and gene therapy products that is fully committed to develop and manufacture to the highest standard the immunotherapies for cancers, today announced the signing of an investment deal with National Science and Technology Development Agency (NSTDA), a government agency that promotes advancement in science and innovation within Thailand. This signing involved all Genepeutic Bio’s stakeholders, including Thai Foods Group Public Company Limited (TFG), Mr.Somphote Ahunai, CEO of Energy Absolute, founders, and other individual investors.
“This is indeed an exciting partnership deal between private and government sectors, which further exemplifies their dedication and commitment to help support local scientific innovation to drive the technology towards commercialization. The high cost of cell and gene therapy overseas makes the treatment almost inaccessible to the local patients. Genepeutic Bio will be the first cell and gene therapy CDMO in Thailand committed to reproducible manufacturing of high-quality, clinical-grade CAR-T cell products. This deal represents a significant investment in making this a reality,” stated Dr.Nares Damrongchai, CEO of Genepeutic Bio.
Under the terms of the agreement, NSTDA contributed 10% of the registered capital of Genepeutic Bio, raising it up to a total of 200 million Baht. This allows NSTDA to have a representative in the board of Genepeutic Bio and the right to vote.
The official signing of the investment deal between Genepeutic Bio and NSTDA occurred at 11:00 am (Bangkok time) at Pullman King Power Bangkok. Alternatively, this event was broadcast live through Facebook.
About Genepeutic Bio Co., Ltd
Genepeutic Bio is the first CDMO in Thailand with an R&D department for Cell and Gene therapy technologies. The company is incorporated in 2020, aiming to deliver Cell and Gene therapy for patients in Thailand and the Asia-Pacific region.
The GMP compliance CDMO will manufacture Chimeric Antigen Receptor (CAR) T-cell products for patients with relapsed/refractory blood cancers, including Acute lymphoid leukemia, Diffuse large B-cell lymphoma, and Multiple myeloma. The CAR T-cell technology is considered a last resource for many cancer patients who failed to respond to conventional treatments such as chemotherapy or targeted therapy. Genepeutic Bio will potentially serve as one of the infrastructures on Cell and Gene therapy technology for Thailand, which will lead to more accessible treatments to Thai and Asia-Pacific patients.
Tel: +66 65 989 4600